Given the role of POLE2 in gastric cancer and other tumours, we speculated that developing pharmacological inhibitors or neutralising antibody target for POLE2 would be of great therapeutic interest to treat human gastric cancer. This evidence concerns the gene POLE2 and gastric cancer.